Targeting the complement system in bacterial meningitis
Bacterial meningitis is most commonly caused by Streptococcus pneumoniae and Neisseria meningitidis and continues to pose a major public health threat. Morbidity and mortality of meningitis are driven by an uncontrolled host inflammatory response. This comprehensive update evaluates the role of the...
Uloženo v:
| Vydáno v: | Brain (London, England : 1878) Ročník 142; číslo 11; s. 3325 |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
01.11.2019
|
| Témata: | |
| ISSN: | 1460-2156, 1460-2156 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Bacterial meningitis is most commonly caused by Streptococcus pneumoniae and Neisseria meningitidis and continues to pose a major public health threat. Morbidity and mortality of meningitis are driven by an uncontrolled host inflammatory response. This comprehensive update evaluates the role of the complement system in upregulating and maintaining the inflammatory response in bacterial meningitis. Genetic variation studies, complement level measurements in blood and CSF, and experimental work have together led to the identification of anaphylatoxin C5a as a promising treatment target in bacterial meningitis. In animals and patients with pneumococcal meningitis, the accumulation of neutrophils in the CSF was mainly driven by C5-derived chemotactic activity and correlated positively with disease severity and outcome. In murine pneumococcal meningitis, adjunctive treatment with C5 antibodies prevented brain damage and death. Several recently developed therapeutics target C5 conversion, C5a, or its receptor C5aR. Caution is warranted because treatment with C5 antibodies such as eculizumab also inhibits the formation of the membrane attack complex, which may result in decreased meningococcal killing and increased meningococcal disease susceptibility. The use of C5a or C5aR antagonists to specifically target the harmful anaphylatoxins-induced effects, therefore, are most promising and present opportunities for a phase 2 clinical trial. |
|---|---|
| AbstractList | Bacterial meningitis is most commonly caused by Streptococcus pneumoniae and Neisseria meningitidis and continues to pose a major public health threat. Morbidity and mortality of meningitis are driven by an uncontrolled host inflammatory response. This comprehensive update evaluates the role of the complement system in upregulating and maintaining the inflammatory response in bacterial meningitis. Genetic variation studies, complement level measurements in blood and CSF, and experimental work have together led to the identification of anaphylatoxin C5a as a promising treatment target in bacterial meningitis. In animals and patients with pneumococcal meningitis, the accumulation of neutrophils in the CSF was mainly driven by C5-derived chemotactic activity and correlated positively with disease severity and outcome. In murine pneumococcal meningitis, adjunctive treatment with C5 antibodies prevented brain damage and death. Several recently developed therapeutics target C5 conversion, C5a, or its receptor C5aR. Caution is warranted because treatment with C5 antibodies such as eculizumab also inhibits the formation of the membrane attack complex, which may result in decreased meningococcal killing and increased meningococcal disease susceptibility. The use of C5a or C5aR antagonists to specifically target the harmful anaphylatoxins-induced effects, therefore, are most promising and present opportunities for a phase 2 clinical trial.Bacterial meningitis is most commonly caused by Streptococcus pneumoniae and Neisseria meningitidis and continues to pose a major public health threat. Morbidity and mortality of meningitis are driven by an uncontrolled host inflammatory response. This comprehensive update evaluates the role of the complement system in upregulating and maintaining the inflammatory response in bacterial meningitis. Genetic variation studies, complement level measurements in blood and CSF, and experimental work have together led to the identification of anaphylatoxin C5a as a promising treatment target in bacterial meningitis. In animals and patients with pneumococcal meningitis, the accumulation of neutrophils in the CSF was mainly driven by C5-derived chemotactic activity and correlated positively with disease severity and outcome. In murine pneumococcal meningitis, adjunctive treatment with C5 antibodies prevented brain damage and death. Several recently developed therapeutics target C5 conversion, C5a, or its receptor C5aR. Caution is warranted because treatment with C5 antibodies such as eculizumab also inhibits the formation of the membrane attack complex, which may result in decreased meningococcal killing and increased meningococcal disease susceptibility. The use of C5a or C5aR antagonists to specifically target the harmful anaphylatoxins-induced effects, therefore, are most promising and present opportunities for a phase 2 clinical trial. Bacterial meningitis is most commonly caused by Streptococcus pneumoniae and Neisseria meningitidis and continues to pose a major public health threat. Morbidity and mortality of meningitis are driven by an uncontrolled host inflammatory response. This comprehensive update evaluates the role of the complement system in upregulating and maintaining the inflammatory response in bacterial meningitis. Genetic variation studies, complement level measurements in blood and CSF, and experimental work have together led to the identification of anaphylatoxin C5a as a promising treatment target in bacterial meningitis. In animals and patients with pneumococcal meningitis, the accumulation of neutrophils in the CSF was mainly driven by C5-derived chemotactic activity and correlated positively with disease severity and outcome. In murine pneumococcal meningitis, adjunctive treatment with C5 antibodies prevented brain damage and death. Several recently developed therapeutics target C5 conversion, C5a, or its receptor C5aR. Caution is warranted because treatment with C5 antibodies such as eculizumab also inhibits the formation of the membrane attack complex, which may result in decreased meningococcal killing and increased meningococcal disease susceptibility. The use of C5a or C5aR antagonists to specifically target the harmful anaphylatoxins-induced effects, therefore, are most promising and present opportunities for a phase 2 clinical trial. |
| Author | Koelman, Diederik L H Brouwer, Matthijs C van de Beek, Diederik |
| Author_xml | – sequence: 1 givenname: Diederik L H surname: Koelman fullname: Koelman, Diederik L H organization: Amsterdam UMC, University of Amsterdam, Department of Neurology, Amsterdam Neuroscience, Meibergdreef 9, AZ, Amsterdam, The Netherlands – sequence: 2 givenname: Matthijs C surname: Brouwer fullname: Brouwer, Matthijs C organization: Amsterdam UMC, University of Amsterdam, Department of Neurology, Amsterdam Neuroscience, Meibergdreef 9, AZ, Amsterdam, The Netherlands – sequence: 3 givenname: Diederik surname: van de Beek fullname: van de Beek, Diederik organization: Amsterdam UMC, University of Amsterdam, Department of Neurology, Amsterdam Neuroscience, Meibergdreef 9, AZ, Amsterdam, The Netherlands |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31373605$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNj0tLxDAUhYOMOA_duZYs3dTJo03apQyOCgNuui83ze0YadPapMj46y04gqtz4Ps4cNZk4XuPhNxy9sBZIbdmBOe38PUthLggK54qlgieqcW_viTrED4Y46kU6oosJZdaKpatiC5hPGJ0_kjjO9K674YWO_SRhlOI2FHnqYE64uigpTOYTRdduCaXDbQBb865IeX-qdy9JIe359fd4yGp04zFRBulUWVNbnSRKwFoC55btNgAFgZNDZwrVSNXRQraFpkVubY6nykHa8WG3P_ODmP_OWGIVedCjW0LHvspVEKoXHKmpJ7Vu7M6mQ5tNYyug_FU_X0VPxEtWUs |
| CitedBy_id | crossref_primary_10_1080_14656566_2019_1685497 crossref_primary_10_1016_j_pediatrneurol_2023_09_020 crossref_primary_10_3389_fimmu_2021_683879 crossref_primary_10_1016_j_intimp_2023_110081 crossref_primary_10_1016_j_jim_2024_113709 crossref_primary_10_1080_21505594_2025_2553781 crossref_primary_10_1080_23744235_2021_1883730 crossref_primary_10_1212_NXI_0000000000001123 crossref_primary_10_3389_fbioe_2023_885877 crossref_primary_10_1093_ofid_ofad159 crossref_primary_10_1093_omcr_omaf051 crossref_primary_10_3390_biom15081179 crossref_primary_10_1002_adma_202311661 crossref_primary_10_1007_s11095_020_02917_6 crossref_primary_10_1186_s12974_019_1675_1 crossref_primary_10_3389_fcimb_2021_803186 crossref_primary_10_4110_in_2025_25_e32 crossref_primary_10_1016_j_cmi_2024_03_012 crossref_primary_10_1371_journal_pone_0332073 crossref_primary_10_1007_s11095_025_03882_8 crossref_primary_10_1177_20499361241274246 crossref_primary_10_3389_fimmu_2020_603924 crossref_primary_10_1093_cid_ciab477 crossref_primary_10_1016_j_micpath_2020_104683 crossref_primary_10_1016_j_micpath_2022_105855 crossref_primary_10_1007_s00415_025_13225_7 crossref_primary_10_3390_molecules26051419 crossref_primary_10_1093_femsre_fuaa072 crossref_primary_10_1080_17843286_2021_1873583 crossref_primary_10_3389_fncel_2023_1228968 crossref_primary_10_1007_s00415_020_10235_5 crossref_primary_10_1007_s11481_022_10055_6 crossref_primary_10_1007_s11427_021_2032_9 crossref_primary_10_1097_IAE_0000000000004565 crossref_primary_10_1186_s12929_024_01029_2 crossref_primary_10_1016_S0140_6736_21_00883_7 crossref_primary_10_1038_s41392_021_00658_5 crossref_primary_10_1186_s13041_021_00890_8 crossref_primary_10_1128_cmr_00060_19 crossref_primary_10_3390_ph13110341 crossref_primary_10_3389_fncel_2021_710390 |
| ContentType | Journal Article |
| Copyright | The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain. |
| Copyright_xml | – notice: The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1093/brain/awz222 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1460-2156 |
| ExternalDocumentID | 31373605 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GroupedDBID | --- -E4 -~X .2P .I3 .XZ .ZR 0R~ 1TH 23N 2WC 4.4 482 48X 53G 5GY 5RE 5VS 5WA 5WD 6PF 70D AABZA AACZT AAIMJ AAJKP AAJQQ AAMDB AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AAUAY AAUQX AAVAP AAVLN AAWTL ABDFA ABEJV ABEUO ABGNP ABIVO ABIXL ABJNI ABKDP ABLJU ABMNT ABNHQ ABNKS ABPQP ABPTD ABQLI ABQNK ABVGC ABWST ABXVV ABXZS ABZBJ ACGFS ACIWK ACPRK ACUFI ACUTJ ACUTO ACYHN ADBBV ADEYI ADEZT ADGKP ADGZP ADHKW ADHZD ADIPN ADNBA ADOCK ADQBN ADRTK ADVEK ADYVW ADZXQ AEGPL AEJOX AEKSI AELWJ AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFGWE AFIYH AFOFC AFXAL AFYAG AGINJ AGKEF AGORE AGQXC AGSYK AGUTN AHGBF AHMBA AHMMS AHXPO AIJHB AJBYB AJEEA AJNCP AKWXX ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN ARIXL ATGXG AXUDD AYOIW BAWUL BAYMD BCRHZ BEYMZ BHONS BQDIO BR6 BSWAC BTRTY BVRKM C45 CDBKE CGR COF CS3 CUY CVF CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBS ECM EE~ EIF EMOBN ENERS F5P F9B FECEO FHSFR FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HZ~ IOX J21 J5H JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B M-Z MHKGH ML0 N9A NGC NLBLG NOMLY NOYVH NPM O9- OAUYM OAWHX OBOKY OCZFY ODMLO OHH OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P PAFKI PEELM PQQKQ Q1. Q5Y R44 RD5 ROL ROX ROZ RUSNO RW1 RXO TCURE TEORI TJX TLC TR2 VVN W8F WH7 WOQ X7H YAYTL YKOAZ YSK YXANX ZKX ~91 7X8 |
| ID | FETCH-LOGICAL-c450t-7b67e65f8b79862aed918dedefae9bebca1166ce1694a7d95d287d78ae91add2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 46 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000504323200014&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1460-2156 |
| IngestDate | Thu Oct 02 09:18:03 EDT 2025 Mon Jul 21 05:55:04 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Keywords | bacterial meningitis therapeutics experimental models complement C5a complement system |
| Language | English |
| License | The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c450t-7b67e65f8b79862aed918dedefae9bebca1166ce1694a7d95d287d78ae91add2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC6821383 |
| PMID | 31373605 |
| PQID | 2268310637 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2268310637 pubmed_primary_31373605 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-11-01 |
| PublicationDateYYYYMMDD | 2019-11-01 |
| PublicationDate_xml | – month: 11 year: 2019 text: 2019-11-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Brain (London, England : 1878) |
| PublicationTitleAlternate | Brain |
| PublicationYear | 2019 |
| SSID | ssj0014326 |
| Score | 2.5199144 |
| SecondaryResourceType | review_article |
| Snippet | Bacterial meningitis is most commonly caused by Streptococcus pneumoniae and Neisseria meningitidis and continues to pose a major public health threat.... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 3325 |
| SubjectTerms | Animals Complement C5a - genetics Complement C5a - immunology Complement System Proteins - cerebrospinal fluid Complement System Proteins - drug effects Complement System Proteins - physiology Humans Immunotherapy Inflammation - etiology Inflammation - pathology Meningitis, Bacterial - immunology Meningitis, Bacterial - pathology Meningitis, Bacterial - therapy Mice |
| Title | Targeting the complement system in bacterial meningitis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31373605 https://www.proquest.com/docview/2268310637 |
| Volume | 142 |
| WOSCitedRecordID | wos000504323200014&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSwMxEB7Uinjx_agvInhd2n0lm5OIWDzY0kMPvS15TKCXbbU-wF_vJJvSkyB42UvYsDtJZr55ZD6Au1waa8g_TpxSmBRIZ05WuqK9TKqPLLZSRbgo_CJGo2o6leMYcFvGssqVTgyK2s6Nj5H3CCZ4Tiyei_vFa-JZo3x2NVJobEInJyjjS7rEdJ1FKPIs3i7qJ2TaeCx8Jye-pz0BQ099fWeeNvc3cBmMzGD_v593AHsRXrKHdj8cwgY2R7AzjAn0YxCTUPlN9ooR8mOhoDwECFnb0pnNGqbbBs40DQ0EPqPZ8gQmg6fJ43MSuRMSU5T990RoLpCXrtJCktOi0Mq0smjRKZTaV0ClKecGUy4LJawsLblOVlQ0mpLKy05hq5k3eA5MZc5w39ZPK3LlHKo-pqp0OSoCZzorunC7kkhNW9PnG1SD849lvZZJF85asdaLtodGTcslcnKlLv7w9iXsEkyR7Q3AK-g4Oph4Ddvmk_7_7SasOT1H4-EPZ6C4vQ |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Targeting+the+complement+system+in+bacterial+meningitis&rft.jtitle=Brain+%28London%2C+England+%3A+1878%29&rft.au=Koelman%2C+Diederik+L+H&rft.au=Brouwer%2C+Matthijs+C&rft.au=van+de+Beek%2C+Diederik&rft.date=2019-11-01&rft.eissn=1460-2156&rft.volume=142&rft.issue=11&rft.spage=3325&rft_id=info:doi/10.1093%2Fbrain%2Fawz222&rft_id=info%3Apmid%2F31373605&rft_id=info%3Apmid%2F31373605&rft.externalDocID=31373605 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1460-2156&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1460-2156&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1460-2156&client=summon |